FDA Approves Pasatru (garetosmab-grts) for the Treatment of Fibrodysplasia Ossificans Progressiva
RegulatoryapprovedPasatruPositive
AI Analysis
Summary
The FDA has approved Pasatru (garetosmab-grts), developed by Regeneron Pharmaceuticals, for the treatment of Fibrodysplasia Ossificans Progressiva. This is a significant regulatory approval for a rare genetic disorder.
Outcome Details
FDA approval granted for Pasatru (garetosmab-grts) to reduce formation of new bone
Importance:9/10
Sentiment:
0.95
FDA approvalrare diseaseRegeneronPasatrugaretosmab-grts
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on August 19, 2026 8:08 PM